期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 12, 页码 7900-7925出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c02055
关键词
-
资金
- National Natural Science Foundation of China [21977128]
- Fundamental Research Funds for the Central Universities [20ykpy117]
- Natural Science Foundation of Guangdong [2018A030313300]
Epigenetic regulation is crucial in physiological processes, with dysregulation linked to diseases like cancer. Covalent small-molecule inhibitors show promise in enhancing selectivity and efficacy, but face challenges.
Epigenetic regulation of gene expression plays a critical role in various physiological processes, and epigenetic dysregulation is implicated in a number of diseases, prominently including cancer. Epigenetic regulators have been validated as potential therapeutic targets, and significant progress has been made in the discovery and development of epigenetic-based inhibitors. However, successful epigenetic drug discovery is still facing challenges, including moderate selectivity, limited efficacy, and acquired drug resistance. Inspired by the advantages of covalent small-molecule inhibitors, targeted covalent inhibition has attracted increasing interest in epigenetic drug discovery. In this review, we comprehensively summarize the structure-based design and characterization of covalent inhibitors targeting epigenetic writers, readers, and erasers and highlight their potential benefits in enhancing selectivity across the enzyme family and improving in vivo efficacy. We also discuss the challenges and opportunities of covalent small-molecule inhibitors and hope to shed light on future epigenetic drug discovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据